Category - Developments

Developments

Eiger initiates rolling NDA for progeria drug candidate

Eiger BioPharmaceuticals (NASDAQ:EIGR) initiated a rolling NDA submission to the FDA for lonafarnib for the treatment of Hutchinson-Gilford progeria syndrome and progeroid laminopathies. Progeria is an extremely rare...

December 17, 2019

Developments

Kamada enrolls first patient in Phase 3 alpha-1 antitrypsin deficiency trial

Kamada (NASDAQ, TASE:KMDA) randomized the first patient in a pivotal clinical trial evaluating its inhaled alpha-1 antitrypsin (AAT) therapy for the treatment of alpha-1 antitrypsin deficiency (AATD). AATD is an...

December 17, 2019

Developments

Kane Biotech launches anti-biofilm shampoo consumer product test

Kane Biotech (TSX-V:KNE) launched a consumer product test to evaluate the efficacy of its new shampoo on dermatitis and dandruff. Research indicates that microbial biofilms may aggravate symptoms associated with...

December 16, 2019

Developments

iBio reports progress on bio-better rituximab collaboration

At last week’s Antibody Engineering & Therapeutics conference in San Diego, CA, iBio (NYSE AMERICAN:IBIO) presented its glycan engineering technologies and plant-based manufacturing platform as a means to rapidly...

December 16, 2019

Developments

OncoSec presents interim Phase 2 data in metastatic triple negative breast cancer

OncoSec Medical (NASDAQ:ONCS) presented interim results from KEYNOTE-890, an ongoing Phase 2 study of its TAVO drug candidate in combination with KEYTRUDA in patients with metastatic, chemotherapy-refractory triple...

December 13, 2019

Developments

BriaCell announces clinical data at 2019 San Antonio Breast Cancer Symposium

BriaCell Therapeutics (TSXV:BCT; OTCQB:BCTXF) presented results of clinical studies with its lead product candidate, Bria-IMT, in combination with immune checkpoint inhibitors in advanced breast cancer at 2019 San...

December 13, 2019

Developments

Soricimed updates peptide-drug conjugate program

Closely-held Soricimed Biopharma updated its peptide-drug conjugate (PDC) program, which enables delivery of a cytotoxic drug payload bound to a targeting peptide directly to receptors that are overexpressed by cancer...

December 12, 2019

Developments

iBio unveils FastGlycaneering Development Service to produce recombinant proteins

iBio (NYSE AMERICAN:IBIO) unveiled its FastGlycaneering Development Service, which includes an array of new glycosylation technologies for engineering high-performance recombinant proteins. Biopharmaceutical innovators...

December 11, 2019

Developments

Hepion advances to next dosing level in ongoing Phase 1 study of CRV431

Hepion Pharmaceuticals (NASDAQ:HEPA) advanced to the next higher dose of CRV431 in its ongoing Phase 1 multiple ascending dose trial in healthy volunteers. The clinical trial management team determined the 75 mg dosing...

December 10, 2019

Developments

Tonix Pharmaceuticals enrolls first patient in Phase 3 fibromyalgia study

Tonix Pharmaceuticals (NASDAQ:TNXP) enrolled the first patient in its Phase 3 study of TNX-102 SL for the management of fibromyalgia. TNX-102 SL is a non-opioid analgesic, administered daily at bedtime. The trial will...

December 10, 2019

Category - Developments

Eiger initiates rolling NDA for progeria drug candidate

Kamada enrolls first patient in Phase 3 alpha-1 antitrypsin deficiency trial

Kane Biotech launches anti-biofilm shampoo consumer product test

iBio reports progress on bio-better rituximab collaboration

OncoSec presents interim Phase 2 data in metastatic triple negative breast cancer

BriaCell announces clinical data at 2019 San Antonio Breast Cancer Symposium

Soricimed updates peptide-drug conjugate program

iBio unveils FastGlycaneering Development Service to produce recombinant proteins

Hepion advances to next dosing level in ongoing Phase 1 study of CRV431

Tonix Pharmaceuticals enrolls first patient in Phase 3 fibromyalgia study

General

More